Why the Odds Are Stacked Against a Promising New Covid Drug

Health
By BY BENJAMIN MUELLER from NYT Health https://ift.tt/PfDykRg
via IFTTT Coronavirus (2019-nCoV), Clinical Trials, Research, Regulation and Deregulation of Industry, Interferon (Protein), Deaths (Fatalities), Paxlovid (Drug), your-feed-healthcare A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon.

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda